Duloxetinedraddress1 (Duloxetinedraddress1)
Duloxetine
Product Images NDC 50090-4709
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-4709). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Duloxetinedraddress2 (Duloxetinedraddress2)
Duloxetinedrfigure1 (Duloxetinedrfigure1)
A line chart depicting the proportion of patients with relapse over time, comparing treatments of Duloxetine versus Placebo. The x-axis represents time (likely in days) up to 200, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. Duloxetine is represented by a solid line, showing a lower proportion of relapse compared to Placebo, which is depicted by a dashed line.*
Duloxetinedrfigure2 (Duloxetinedrfigure2)
A Kaplan-Meier curve chart showing the proportion of patients with relapse over time from randomization to relapse in days. The chart compares two groups: one treated with Duloxetine and the other with placebo, indicated by different line styles. The y-axis represents the proportion of patients with relapse, and the x-axis shows time in days.*
Duloxetinedrfigure3 (Duloxetinedrfigure3)
A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Four lines compare Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, indicating patient response rates to different dose regimens of Duloxetine and placebo over a range of pain improvement percentages.*
Duloxetinedrfigure4 (Duloxetinedrfigure4)
A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The graph shows three trend lines representing each treatment group over a range of pain improvement percentages.*
Duloxetinedrfigure7 (Duloxetinedrfigure7)
A line graph comparing the percentage of patients improved over varying percent improvements in pain from baseline, showing two curves representing placebo and Duloxetine 60/120 mg once daily groups.*
Duloxetinedrfigure8 (Duloxetinedrfigure8)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The graph shows two lines, one for Duloxetine and one for placebo, plotting patient improvement across a range of pain reduction percentages.*
Duloxetinedrfigure9 (Duloxetinedrfigure9)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two curves that track patient improvement across multiple pain reduction thresholds.*
Duloxetinedrstructure (Duloxetinedrstructure)
Chemical structure of duloxetine hydrochloride showing its molecular framework with notation for stereochemistry (S) and the hydrochloride salt form.*
Label Image (Lbl500904709)
Label for Duloxetine delayed-release capsules from A-S Medication Solutions, NDC 50090-4709. The label indicates 20 mg strength, unit dose in a 44 capsule blister pack, with storage instructions and lot number details.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
